Eli Lilly (LLY) Construction in Progress (2012 - 2024)
Eli Lilly posted quarterly Construction in Progress of $8.2 billion for Q4 2024, up 62.17% year-on-year from $5.1 billion in Q1 2024, and up 62.17% on a QoQ basis from $5.1 billion in Q4 2023.
Eli Lilly (LLY) has 13 years of Construction in Progress data on file, last reported at $8.2 billion in Q4 2024.
- For the quarter ending Q4 2024, Construction in Progress rose 62.17% year-over-year to $8.2 billion; the trailing twelve-month figure through Dec 2024 stood at $8.2 billion (up 62.17% YoY), and the FY2024 full-year result was $8.2 billion, up 62.17% from the prior year.
- Construction in Progress for Q4 2024 stood at $8.2 billion, up from $5.1 billion in the prior quarter.
- Across five years, Construction in Progress topped out at $8.2 billion in Q4 2024 and bottomed at $2.1 billion in Q4 2020.
- The 5-year median for Construction in Progress is $2.8 billion (2022), against an average of $4.1 billion.
- The widest annual swing landed in 2021, when Construction in Progress climbed 1.82%; it then soared 81.67% in 2023.
- A 5-year view of Construction in Progress shows it stood at $2.1 billion in 2020, then rose by 1.82% to $2.2 billion in 2021, then climbed by 28.51% to $2.8 billion in 2022, then surged by 81.67% to $5.1 billion in 2023, then jumped by 62.17% to $8.2 billion in 2024.
- The last three Construction in Progress figures came in at $8.2 billion (Q4 2024), $5.1 billion (Q4 2023), and $2.8 billion (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 8.24 Bn |
| Dec 31, 2023 | 5.08 Bn |
| Dec 31, 2022 | 2.80 Bn |
| Dec 31, 2021 | 2.18 Bn |
| Dec 31, 2020 | 2.14 Bn |
| Dec 31, 2019 | 1.88 Bn |
| Dec 31, 2018 | 1.59 Bn |
| Dec 31, 2017 | 1.78 Bn |
| Dec 31, 2016 | 1.80 Bn |
| Dec 31, 2015 | 1.67 Bn |
| Dec 31, 2014 | 1.70 Bn |
| Dec 31, 2013 | 1.21 Bn |
| Dec 31, 2012 | 799.90 Mn |